Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients. 2016

Mark McCauley, and Sharath Vallabhajosyula, and Dawood Darbar
Division of Cardiology, Department of Medicine, University of Illinois at Chicago, 840 South Wood Street, Suite 920 (MC715), Chicago, IL 60612, USA.

The most common arrhythmia requiring drug treatment is atrial fibrillation (AF), which affects 2 to 5 million Americans and continues to be a major cause of morbidity and increased mortality. Despite recent advances in catheter-based and surgical therapies, antiarrhythmic drugs continue to be the mainstay of therapy for most patients with symptomatic AF. However, many antiarrhythmics block the rapid component of the cardiac delayed rectifier potassium current (IKr) as a major mechanism of action, and marked QT prolongation and pause-dependent polymorphic ventricular tachycardia (torsades de pointes) are major class toxicities.

UI MeSH Term Description Entries
D008297 Male Males
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D001145 Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction. Arrhythmia,Arrythmia,Cardiac Arrhythmia,Cardiac Arrhythmias,Cardiac Dysrhythmia,Arrhythmia, Cardiac,Dysrhythmia, Cardiac
D016171 Torsades de Pointes A malignant form of polymorphic ventricular tachycardia that is characterized by HEART RATE between 200 and 250 beats per minute, and QRS complexes with changing amplitude and twisting of the points. The term also describes the syndrome of tachycardia with prolonged ventricular repolarization, long QT intervals exceeding 500 milliseconds or BRADYCARDIA. Torsades de pointes may be self-limited or may progress to VENTRICULAR FIBRILLATION. Torsade de Pointes,Pointes, Torsade de,Pointes, Torsades de,de Pointes, Torsade,de Pointes, Torsades
D026902 Potassium Channel Blockers A class of drugs that act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of ACTION POTENTIALS. They are used as ANTI-ARRHYTHMIA AGENTS and VASODILATOR AGENTS. Channel Blockers, Potassium,Potassium Channel Blocker,Blocker, Potassium Channel,Blockers, Potassium Channel,Channel Blocker, Potassium

Related Publications

Mark McCauley, and Sharath Vallabhajosyula, and Dawood Darbar
June 2016, Cardiac electrophysiology clinics,
Mark McCauley, and Sharath Vallabhajosyula, and Dawood Darbar
March 2005, Orvosi hetilap,
Mark McCauley, and Sharath Vallabhajosyula, and Dawood Darbar
January 1990, Progress in clinical and biological research,
Mark McCauley, and Sharath Vallabhajosyula, and Dawood Darbar
January 1991, The Yale journal of biology and medicine,
Mark McCauley, and Sharath Vallabhajosyula, and Dawood Darbar
December 1993, The Journal of pharmacology and experimental therapeutics,
Mark McCauley, and Sharath Vallabhajosyula, and Dawood Darbar
June 2016, Cardiac electrophysiology clinics,
Mark McCauley, and Sharath Vallabhajosyula, and Dawood Darbar
January 1989, Pflugers Archiv : European journal of physiology,
Mark McCauley, and Sharath Vallabhajosyula, and Dawood Darbar
June 2016, Cardiac electrophysiology clinics,
Mark McCauley, and Sharath Vallabhajosyula, and Dawood Darbar
January 1989, Pflugers Archiv : European journal of physiology,
Mark McCauley, and Sharath Vallabhajosyula, and Dawood Darbar
January 2017, Acta physiologica (Oxford, England),
Copied contents to your clipboard!